SecBot SecBot
8-K ·Filed Feb 25, 2026

RCUS

Arcus Biosciences, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago SEC0001724521-26-000007
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The strong clinical data for casdatifan could drive investor interest despite declining revenue, but traders should monitor upcoming data readouts in 2026 and the futility analysis of the STAR-121 program which could impact R&D expense trajectory.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$19.54
T+0 close · Feb 25, 2026 · via day close
Latest settled
+19.91%
T+60 · $23.43
Vs SPY
+11.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $19.54entry
  2. T+1 · 9mo ago +4.25%α +4.73% · $20.37
  3. T+5 · 9mo ago +13.66%α +14.82% · $22.21
  4. T+20 · 8mo ago +8.55%α +14.96% · $21.21
  5. T+60 · 6mo ago +19.91%α +11.73% · $23.43
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arcus Biosciences reported Q4 and full-year 2025 financial results, highlighting strong clinical data for its drug candidate casdatifan in kidney cancer, including a median progression-free survival of 15.1 months and a 45% response rate. The company maintains a robust $1 billion cash position with runway into 2028, while R&D expenses increased to $121 million in Q4. Revenue declined slightly to $33 million from $36 million year-over-year.

Key Financial Metrics

Revenue
$33.0M
-8.3% YoY
EPS
$-0.89

Key Facts

  • Updated data for casdatifan showed 15.1 months median PFS and 45.2% confirmed response rate in 100mg cohort
  • Cash, cash equivalents and marketable securities were $1.0 billion as of December 31, 2025
  • Q4 2025 revenue was $33 million, down from $36 million in Q4 2024
  • Q4 2025 R&D expenses were $121 million, up from $111 million in Q4 2024
  • Net loss was $106 million for Q4 2025, compared to $94 million for Q4 2024
  • Company expects cash runway until at least second half of 2028

Financial Impact

Revenue decreased by $3 million year-over-year while R&D expenses increased by $10 million, resulting in a wider net loss of $106 million (up from $94 million)

revenuer&d expensesnet losscash position

Risk Factors

  • R&D expenses increased while revenue declined, widening net loss
  • Futility analysis of STAR-121 program could lead to termination of key development program
  • Dependence on successful clinical trial outcomes for casdatifan and quemliclustat

Market Snapshot

Exchange
NYSE

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001724521-26-000007
Document: 0001724521-26-000007-index-headers.html0001724521-26-000007
Document: 0001724521-26-000007-index.html0001724521-26-000007
Document: 0001724521-26-000007.txt0001724521-26-000007

Track record

13 reports on RCUS

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +4.24% at T+1 after the Oct 21, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $16.95 Now $16.86 −0.53% settles Nov 23
  2. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $18.95 to $16.86 Now $16.86 −11.03% ▼ −11.03% −9.34% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $17.69 to $17.77 Now $16.86 −4.69% ▲ +0.45% −2.84% vs SPY
  4. Oct 23, 202624d ago 8-K Bearish 5/10 Entry $17.76 to $18.19 Now $16.86 +5.07% ▼ −2.42% −3.68% vs SPY
  5. Oct 22, 202625d ago 424B5 Bearish 6/10 Entry $18.54 to $18.19 Now $16.86 +9.06% ▲ +1.89% +1.33% vs SPY
  6. Oct 21, 202626d ago 424B5 Bearish 5/10 Entry $19.36 to $18.61 Now $16.86 +12.91% ▲ +3.87% +4.58% vs SPY
  7. Oct 21, 202626d ago 8-K Neutral 4/10 Entry $19.36 to $18.61 Now $16.86 −12.91% ▼ −3.87% −4.58% vs SPY
  8. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $23.75 to $18.14 Now $16.86 −29.01% ▼ −23.62% −23.70% vs SPY
  9. Jul 9, 202618w ago 144 Neutral 3/10 Entry $28.92 to $26.64 Now $16.86 −41.70% ▼ −7.88% −7.32% vs SPY
  10. Apr 21, 202629w ago DEFA14A Neutral 2/10 Entry $26.62 to $24.55 Now $16.86 −36.66% ▼ −7.79% −7.85% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026